04.01.10 Oslo – Norwegian drug delivery specialist Clavis Pharma ASA has received an unsecured loan of NOK20m (EUR2.4m) from the governmental body Innovation Norway to kick-off a Phase III registration trial with elacytarabine in 350...
more
21.01.09 The Norwegian government is discussing a €300m rescue package for the biotech industry as part of a national financial rescue plan. The proposal for the plan was put forward by the academic institutes, hospitals and businesses...
more
19.08.08 Oslo – Photocure ASA, one of the Norwegian biotech companies established around the Radium Hospital in Oslo, has finished its demerger and set up a new company named PCI Biotech. In June, the former subsidary raised EUR7.6m (NOK...
more
14.08.08 Oslo –Algeta A/S has started a Phase III study of its bone-targeting radium-223 drug Alpharadin that will enrol 750 men with advanced, hormone-refractory prostate cancer (HRPC). The primary efficacy endpoint of the trial is...
more
26.03.08 Algeta ASA (Oslo) is to commence clinical development of Alpharadin™ in hormone-refractory prostate cancer (HRPC) patients in the US. An initial Phase I pharmacokinetics, biodistribution and dosimetry study (BC1-08) with...
more
